This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

More Hot Biotech Trades for Second Half 2011

Stocks in this article: TRGT AVEO THLD RPTP ANX SNGX.OB VRTX

BOSTON ( TheStreet) -- Here are some more top biotech stock trades for the second half of 2011.

The biotech stock trades listed on the following pages encompass pending FDA drug approval decisions and clinical trial results -- all of which have the potential to produce significant stock-price volatility in the next six months.

These biotech stock events/trades expected before 2011 finishes build on the list of 10 biotech stock trades that I compiled and published last week.

Represented below are an additional five pending FDA drug approvals, four phase III clinical trials and five phase II clinical trials -- all of which should occur in the second half of the year.

Targacept (TRGT)
The event: Phase III study of TC-5214 as add-on therapy for patients with major depressive disorder.
The timelines: Top-line results from one or more of the four phase III studies expected in the fourth quarter.
The stakes: Targacept partner AstraZeneca (AZN) is conducting a large phase III study program for TC-5214 in major depressive disorder. TC-5214 is a potential blockbuster depression drug if the phase III studies are successful.

Aveo Pharmaceuticals (AVEO)
The event: Phase III study of tivozanib in kidney cancer.
The timeline: Top-line results expected in the fourth quarter.
The stakes: Tivozanib, Aveo's lead drug, is being compared against Onyx Pharmaceuticals' (ONXX) Nexavar in first-line, advanced renal cell carcinoma, or kidney cancer. The study is designed to show that tivozanib can extend the time before tumors regrow or patients die compared to Nexavar.

Threshold Pharmaceuticals (THLD)
The event: Phase II study of TH-302 in pancreatic cancer
The timeline: Top-line results expected in the fourth quarter.
The stakes: After a previous pancreatic cancer drug failed, Threshold is back developing another drug known as TH-302. The phase II study compares TH-302 plus the chemotherapy drug gemcitabine against gemcitabine alone in patients with first-line pancreatic cancer. The study is designed to show that the addition of TH-302 to gemcitabine can prolong the time before tumors start to grow.

1 of 4

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,778.15 +421.28 2.43%
S&P 500 2,061.23 +48.34 2.40%
NASDAQ 4,748.3960 +104.0840 2.24%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs